Effect of Ranolazine on Valvular Disease in Patients With Pacemakers
NCT ID: NCT01979965
Last Updated: 2013-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
50 participants
INTERVENTIONAL
2013-11-30
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active drug
Ranolazine therapy for three months
Ranolazine (Active drug)
Ranolazine therapy for three months
Sugar Pill
sugar pill therapy for three months
Placebo
Placebo therapy for three months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ranolazine (Active drug)
Ranolazine therapy for three months
Placebo
Placebo therapy for three months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate or severe mitral regurgitation AND
* Cardiac resynchronization therapy (CRT) ≥ 3 months prior to enrollment AND
* Maximal Medical Therapy (ACE-Inhibitor, beta blocker, aldosterone antagonist, diuretic, aspirin, statin)
Exclusion Criteria
* active heart failure
* current ranolazine therapy
* congenital heart disease
* mechanical valve prostheses
* vegetation/endocarditis
* significant pulmonary disease
* peripheral vascular disease
* trivial or mild mitral regurgitation
* creatinine clearance \< 30 mL/min
* liver cirrhosis
* strong inhibitors of CYP3A (including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir)
* strong inducers of CYP3A (including rifampin, rifapentine, phenobarbital, phenytoin, carbamazepine and St.John's wort)
* Strong P-glycoprotein inhibitors (including cyclosporine, verapamil, and quinidine)
* Initial QTc interval ≥ 440msec
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Cardiology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raj Baljepally, MD
Role: PRINCIPAL_INVESTIGATOR
University Cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Cardiology
Knoxville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University Cardiology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IN-US-259-0173
Identifier Type: -
Identifier Source: org_study_id